健康元：股子公司丽珠集团注射用JP-1366临床试验申请获批

Group 1 - The core point of the article is that Health元 (600380) announced the approval of clinical trials for its injectable drug JP-1366, aimed at treating bleeding from peptic ulcers [1] Group 2 - The approval was granted by the National Medical Products Administration, indicating regulatory support for the company's new drug development [1] - The clinical trial approval is a significant step for the company as it seeks to expand its product offerings in the pharmaceutical market [1]